Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year [Yahoo! Finance]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Yahoo! Finance
Revenue Growth : Total revenues of $116.9 million in 2023, with a significant increase in REZLIDHIA net product sales. Costs and Expenses : Decreased to $137.4 million in 2023 from $175.8 million in 2022. Liquidity Position : Cash, cash equivalents, and short-term investments of $56.9 million as of December 31, 2023. Warning! GuruFocus has detected 7 Warning Signs with RIGL. On March 5, 2024, Rigel Pharmaceuticals Inc ( NASDAQ:RIGL ) released its 8-K filing , detailing the financial results for the fourth quarter and the full year ended December 31, 2023. Rigel, known for developing small-molecule drugs for autoimmune, cancer-related, and viral diseases, including its flagship products TAVALISSE and REZLIDHIA, reported a net income of $0.7 million for the fourth quarter, equating to $0.00 per basic and diluted share. This is a slight decrease from the net income of $1.4 million, or $0.01 per basic and diluted share, for the same period in 2022. Financial Performance and Cha
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdatePR Newswire
- Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy [Seeking Alpha]Seeking Alpha
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma [Yahoo! Finance]Yahoo! Finance
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaPR Newswire
RIGL
Earnings
- 3/5/24 - Beat
RIGL
Sec Filings
- 4/12/24 - Form 8-K
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- RIGL's page on the SEC website